Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft-Versus-Leukemia

Graft-versus-host disease and graft-versus-leukemia.

Allogeneic bone marrow transplantation (BMT) remains the treatment of choice for a number of malignant conditions. Much of the therapeutic potential of this procedure for these diseases relates to the graft-versusleukemia (GVL) effect, which eradicates host malignancy after BMT and is mediated by donor T and natural killer (NK) cells (1). GVL effects are closely associated, however, with graft-...

Graft-versus-host disease or graft-versus-host-like syndrome.

Graft Versus Host Disease

Commonly referred to as GVHD, graft-versus-host disease is a man-made condition that arises when patients are transplanted with donor tissue that is not identical to their own. Transplants from other individuals are called allogeneic (‘allo’ meaning ‘other’ and ‘geneic’ referring to ‘genes’). GVHD occurs after hematopoietic stem cell or bone marrow transplantation but is most commonly experienc...

Graft versus Host Disease

Definition Graft-versus-host disease (GVHD) is the most common complication of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT, the patient’s bone marrow is destroyed with chemotherapy and/or radiation and replaced by donor hematopoietic stem cells. In allogeneic HSCT the donor is usually a close family member or occasionally someone outside the family who has been found to b...

Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Hematopoietic stem cell transplantation is the only curative treatment for many malignant hematologic diseases, with an often critical graft-versus-leukemia effect. Despite peritransplant prophylaxis, GVHD remains a significant cause of posthematopoietic stem cell transplantation morbidity and mortality. Traditional therapies have targeted T cells, yet immunostimulatory dendritic cells (DCs) ar...